AN INDIRECT TREATMENT COMPARISON (ITC) OF IFINATAMAB DERUXTECAN (I-DXD) VERSUS REAL-WORLD PHYSICIAN’S CHOICE OF THERAPY (RWPCT) IN PATIENTS PREVIOUSLY TREATED WITH AT LEAST 2 LINES OF THERAPY (LOTS) FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER...
Author(s)
Jie Meng, MIHMEP1, Jingjing Yin, PhD1, Françoise Diamand, MSc2, Maha Karnoub, PhD1, Sajid Ahmed, PharmD1, Carsyn Norway, PharmD1, Kamya Sankar, MD3.
1Daiichi Sankyo, Inc., Basking Ridge, NJ, USA, 2Daiichi Sankyo France SAS, Rueil-Malmaison, France, 3Cedars-Sinai Medical Center, Samuel Oschin Cancer Center, Los Angeles, CA, USA.
1Daiichi Sankyo, Inc., Basking Ridge, NJ, USA, 2Daiichi Sankyo France SAS, Rueil-Malmaison, France, 3Cedars-Sinai Medical Center, Samuel Oschin Cancer Center, Los Angeles, CA, USA.
OBJECTIVES: Patients with ES-SCLC experience rapid disease progression and have limited treatment options and poor outcomes. The B7-H3-directed antibody-drug conjugate I-DXd demonstrated promising efficacy in patients with previously treated ES-SCLC in the Phase 2 IDeate-Lung01 study (NCT05280470). Given the lack of a comparator arm in IDeate-Lung01, an ITC was conducted to contextualize the results to current standard therapies using real-world data collected for a US Flatiron Health database analysis (Sankar et al, ISPOR 2025, abstract RWD155), to help inform the future role of I-DXd in managing patients with previously treated ES-SCLC.
METHODS: The I-DXd cohort (n=105) included adults who received I-DXd 12 mg/kg as third- or fourth-line treatment in IDeate-Lung01 (data cutoff: March 3, 2025). The real-world cohort (n=297) included adults with ES-SCLC who initiated first-line rwPCT in/after January 2018 and received third-line or fourth-line rwPCT (chemotherapy [including lurbinectedin], anti-PD-[L]1, or chemotherapy + anti-PD-[L]1) in/before June 2023. Matching-adjusted indirect comparison methodology was used to weight patients in the I-DXd cohort to adjust for differences in key prognostic factors and treatment-effect modifiers between cohorts. Overall survival (OS), progression-free survival (PFS), and time to treatment discontinuation (TTD) were compared.
RESULTS: In the real-world cohort, mean age was 65.1 years; 75.8% of patients had received 2 prior LOTs, and 24.2% had received 3 prior LOTs; patient characteristics were similar in the weighted I-DXd cohort (effective sample size, 68.5). PFS and OS were significantly longer with I-DXd than with rwPCT: median (95% CI) PFS was 4.3 (3.2-5.4) versus 2.8 (2.5-3.1) months, and median (95% CI) OS was 10.4 (9.4-14.0) versus 6.1 (5.1-6.8) months. Results for TTD were consistent with PFS.
CONCLUSIONS: I-DXd demonstrated longer OS, PFS, and TTD than rwPCT in this ITC, supporting its potential as a promising treatment option for patients with previously treated ES-SCLC.
METHODS: The I-DXd cohort (n=105) included adults who received I-DXd 12 mg/kg as third- or fourth-line treatment in IDeate-Lung01 (data cutoff: March 3, 2025). The real-world cohort (n=297) included adults with ES-SCLC who initiated first-line rwPCT in/after January 2018 and received third-line or fourth-line rwPCT (chemotherapy [including lurbinectedin], anti-PD-[L]1, or chemotherapy + anti-PD-[L]1) in/before June 2023. Matching-adjusted indirect comparison methodology was used to weight patients in the I-DXd cohort to adjust for differences in key prognostic factors and treatment-effect modifiers between cohorts. Overall survival (OS), progression-free survival (PFS), and time to treatment discontinuation (TTD) were compared.
RESULTS: In the real-world cohort, mean age was 65.1 years; 75.8% of patients had received 2 prior LOTs, and 24.2% had received 3 prior LOTs; patient characteristics were similar in the weighted I-DXd cohort (effective sample size, 68.5). PFS and OS were significantly longer with I-DXd than with rwPCT: median (95% CI) PFS was 4.3 (3.2-5.4) versus 2.8 (2.5-3.1) months, and median (95% CI) OS was 10.4 (9.4-14.0) versus 6.1 (5.1-6.8) months. Results for TTD were consistent with PFS.
CONCLUSIONS: I-DXd demonstrated longer OS, PFS, and TTD than rwPCT in this ITC, supporting its potential as a promising treatment option for patients with previously treated ES-SCLC.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
RWD122
Topic
Real World Data & Information Systems
Topic Subcategory
Health & Insurance Records Systems
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, SDC: Oncology